Table 1.
Patient demographics and disease characteristics at baseline
| Characteristic | All patients (N = 47) |
|---|---|
| Median age (range), y | 29 (6–72) |
|
| |
| Male sex, n (%)a | 29 (61.7) |
|
| |
| Race, n (%)a | |
| White | 36 (83.7) |
| Black or African American | 3 (7.0) |
| Other | 4 (8.5) |
| Missing | 4 (8.5) |
|
| |
| Type of primary cancer, n (%)a | |
| ALL | 44 (93.6) |
| B-ALL | 25 (53.2) |
| T-ALL | 19 (40.4) |
| LL | 3 (6.4) |
| B-LL | 1 (2.1) |
| T-LL | 2 (4.3) |
|
| |
| ECOG performance status, n (%)a | |
| 0 | 4 (13.8) |
| 1 | 21 (72.4) |
| 2 | 4 (13.8) |
| Missing | 18 (38.3) |
|
| |
| Median prior lines of therapy (range) | 4 (1–10) |
|
| |
| Key prior treatments, n (%) | |
| Asparaginase or PEG-asparaginase | 28 (59.6) |
| Blinatumomab | 13 (27.7) |
| Inotuzumab ozogamicin | 7 (14.9) |
| CAR T-cell therapy | 6 (12.8) |
| Daratumumab | 1 (2.1) |
| Venetoclax | 4 (8.5) |
|
| |
| Prior transplant, n (%) | 13 (27.7) |
|
| |
| Median time from diagnosis to first dose (range), mo | 24.7 (1.4–170.3) |
|
| |
| Median time since last prior therapy (range), mo | 1.5 (0.1–21.2) |
|
| |
| Bone marrow blasts | |
| Median (range), % | 51.7 (0.0–99.0) |
| Patients with <5%, n (%)b | 7 (14.9) |
a
Percentages calculated based on total number of patients with available data.
b
Includes all patients (ALL and LL). Patients with relapsed/refractory ALL and LL with measurable disease, as defined as any measurable bone marrow blast percentage or detectable minimal residual disease, were allowed to enroll.
Abbreviations: ALL, acute lymphoblastic leukemia; B-ALL, B-cell acute lymphoblastic leukemia; B-LL, B- cell lymphoblastic lymphoma; CAR, chimeric antigen receptor; ECOG, Eastern Cooperative Oncology Group; LL, lymphoblastic lymphoma; T-ALL, T-cell acute lymphoblastic leukemia; T-LL, T-cell lymphoblastic lymphoma.